HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


CDER Talks Switches, Monograph 'More Than Ever,' But Mum On Changes

This article was originally published in The Tan Sheet & The Rose Sheet

Executive Summary

Officials from FDA's drug center describe their work on the Nonprescription Safe Use Regulatory Expansion initiative and on the center's evaluation of potential solutions to the OTC drug monograph process logjam. A CDER attorneys says FDA" is working towards finalizing" an NSURE regulatory framework.

You may also be interested in...

Switch Paradigm Change Sees Long Road, Breeds Questions

Industry has opposed establishing an intermediate class of drugs between Rx and OTC, and FDA has held it does not have authority to require firms to allow products to be approved for behind-the-counter access or some other alternative distribution. But the creation of some form of third route to access appears likely.

Consent Decree Shuts Down Utah Supplement Marketer After FDA Allowed Five Years To Comply

Three warnings during inspections, a warning letter and meeting with FDA officials didn’t stop Grandma’s Herbs from using drug claims. FTC reimburses consumers who bought three supplements deceptively marketed as treatments for pain and other health conditions related to aging.

J&J Has 18.2% OTC Drug Sales Increase In Hand, But Not Decision On Talc Business Bankruptcy Plan

J&J reported worldwide consumer health and personal care product Q3 sales up 4.1% to $3.7bn driven by 18.2% increase in OTC drug sales. Excluding OTC, its consumer business results would have been down as sales for all other sectors slipped.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts